406
Participants
Start Date
April 7, 2021
Primary Completion Date
March 31, 2031
Study Completion Date
March 31, 2031
CETEG
At progression, patients without prior radiotherapy will undergo radiotherapy and PCV as an adjunct chemotherapy if bone marrow reserve allows in the experimental arm.
PCV
In the comparator arm there is the option for second radiotherapy or even reuse of the full radiochemotherapy regimen as it had been given at diagnosis (BIC).
RT
Radiotherapy at 50.4/54 Gy in 1.8 Gy fractions for grade 2 and 59.4 Gy in 1.8 Gy fractions for grade 3 gliomas
RECRUITING
Charité, University Medicine Berlin, Neurosurgery, Berlin
RECRUITING
Helios Hospital Schwerin, Neurosurgery, Schwerin
RECRUITING
University Clinic Muehlenkreis, Minden, Minden
RECRUITING
University Hospital Göttingen, Neurosurgery, Göttingen
RECRUITING
University Hospital Duesseldorf, Neurooncology, Düsseldorf
RECRUITING
Knappschaftskrankenhaus Bochum GmbH, Neurology Clinic, Bochum
RECRUITING
University Hospital Cologne, Neurosurgery, Cologne
RECRUITING
University Hospital Bonn, Neurology Clinic, Bonn
RECRUITING
University Hospital Frankfurt, Neurooncology, Frankfurt
RECRUITING
University Hospital Saarland, Neurosurgery, Homburg
RECRUITING
University Hospital Mannheim, Neurology Clinic, Mannheim
RECRUITING
University Hospital Heidelberg, Department of Neurooncology, Heidelberg
RECRUITING
University Hospital Tuebingen, Neurooncology, Tübingen
RECRUITING
University Hospital rechts der Isar, Radiation Oncology, Munich
RECRUITING
University Hospital Regensburg, Neurology Clinic, Regensburg
RECRUITING
University Hospital Wuerzburg, Neurosurgery, Würzburg
RECRUITING
Chemnitz Hospital, Neurosurgery, Chemnitz
RECRUITING
University Hospital of Jena, Neurosurgery, Jena
RECRUITING
University Hospital Leipzig, Radiation Therapy, Leipzig
Universitätsmedizin Mannheim
OTHER
Ruhr University of Bochum
OTHER
University Hospital Heidelberg
OTHER